+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti-Hypertensive Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

  • PDF Icon

    Report

  • 90 Pages
  • December 2021
  • Region: Global
  • Acute Market Reports
  • ID: 5616036
Hypertension is most commonly observed chronic disease, which causes elevation in systolic and diastolic blood pressure, which in long term is high risk factor for coronary artery disease, heart failure, stroke etc. The anti-hypertensive drugs are used to control the blood pressure. The antihypertensive drugs market major drivers is the prevalence of the chronic disease along with growing population and altering lifestyle, with increase in awareness of treatment, new drug approval and healthcare expenditure.

The report titled “Global Anti-Hypertensive Drugs Market - Growth, Share, Opportunities and Competitive Analysis, 2021-2029” offers strategic insights into the overall anti-hypertensive drugs market along with the market size and estimates for the duration 2021 to 2029. The said research study covers in-depth analysis of multiple market segments based on type of drug class and different geographical region. The Drug class type segment studied for analyzing the overall anti-hypertensive drugs market is majorly segmented into Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in anti-hypertensive drugs market, pipeline analysis, attractive investment proposition market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global anti-hypertensive drugs market is studied for the following regional markets:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of LATAM
- Middle East and Africa
Market size and forecast for these regional and country level markets are presented in this study for the period 2018-2029. Market growth rates for the forecast period 2021-2029 are also included in this report, considering 2020 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global anti-hypertensive drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global anti-hypertensive drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global anti-hypertensive drugs market. In-depth competitive environment analysis and historical years (2018 & 2019) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global anti-hypertensive drug market, offering market size and estimates for the period from 2021 to 2029, keeping in mind the above-mentioned factors.

Based on the type of drug class, the global Anti-Hypertensive Drugs market is segmented as follows:
- Diuretics
- ACE inhibitors
- ARBs
- Calcium Channel Blockers
- Beta - Adrenergic blocker
- Alpha - Adrenergic blocker
- Central Sympatholyics
- Renin inhibitors
- Vasodilators
The global Anti-Hypertensive Drugs market is segmented by drug class into different categories such as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators. The ACE inhibitors controls the blood pressure by the by widening the blood vessel, which improve the blood flood of the heart. ACE inhibitor dominates the market share of the antihypertensive drugs market in value due to its mechanism of action, preference in geriatric population and cost. The next followed is beta blockers in antihypertensive drugs market which preferred by physician to reduce the blood pressure and risk of complication which is generally associated with chronic hypertension is less, plus with minimal side effects. Diuretic is next most commonly used anti-hypertensive drug in the market, as they are widely available and less expensive compared to others. The diuretics help in maintain the blood pressure by getting rid of the sodium and water. Diuretic is conventionally used first line of treatment, though the trend is changing with new drug entrants approval and different mechanism of action which is further preferred by physician depending upon the suitability of the patient medical history; due to which ACE, Beta blocker, CCB, ARB etc. are used now-days and exist in market according to patient needs.

For the purpose of this study, the Global Anti-Hypertensive Drugs Market is categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
The global anti-hypertensive drugs market is bifurcated into four regions: North America, Europe, Asia-Pacific, Latin America and Middle East. The global Anti-Hypertensive Drug market is dominated by the North America region occupying the major market. The major contributor in this region is US due to factors such as the prevalence of hypertension, rise in geriatric population, upcoming new drug in pipeline and use of combination therapy. Europe is next followed up market with major contributor being UK, Germany, France, Italy and Spain. According to research studies, with rise in population of Europe, there is considerable increase in number of people suffering from hypertension, therefore to address the unmet need for appropriate health care planning and expenditure are the major driving factors for the European market. The Asia-pacific is the lucrative market, with major contributors being Japan, India and China. Asia-Pacific carries almost half of the world cardiovascular burden, in which upto 66% of subtype of CVD contribute to hypertension due to increase in urbanization and adoption of unhealthy lifestyle and food. Thus developed countries dominates the market of hypertensive, emerging economies with growing population and increasing government spending on health care is lucrative market.




This product will be delivered within 2 business days.

Table of Contents

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Anti-Hypertensive Drugs Market Portraiture
2.2 Global Anti-Hypertensive Drugs Market Share, by Drug type, 2020 (US$ Mn)
2.3 Global Anti-Hypertensive Drugs Market, by Geography, 2020 (Value %)
Chapter 3 Global Anti-Hypertensive Drugs Market Analysis
3.1 Hypertension
3.1.1 Epidemiology
3.1.2 Treatment
3.2 Prescription Analysis
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Prevalence of chronic diseases
3.3.1.2 Rise in R&D and new drug approval
3.3.2 Challenges
3.3.2.1 Adverse effects of anti-hypertensive
3.3.3 Opportunities
3.3.3.1 Use of combination therapy and to address the unmet needs
3.4 Attractive Investment Proposition
3.5 Pipeline Analysis
3.6 Market Positioning of Key Players in Anti-Hypertensive Drugs
Chapter 4 Global Anti-Hypertensive Drugs Market Analysis, by Drug Type, 2019-2029 (US$ Mn)
4.1 Introduction
4.2 Diuretics
4.3 ACE inhibitors
4.4 ARBs
4.5 Calcium Channel Blockers
4.6 Beta - Adrenergic blocker
4.7 Alpha - Adrenergic blocker
4.8 Central Sympatholyics
4.9 Renin inhibitors
4.10 Vasodilators
Chapter 5 Global Anti-Hypertensive Drugs Market, by Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)
Chapter 6 Company Profiles
6.1 Novartis AG
6.2 Astra zeneca
6.3 Daiichyi Sankyo Co. Ltd
6.4 Takeda Pharmaceutical
6.5 Sanofi
6.6 Merck & Co
6.7 Boehinger Ingelheim
6.8 Pfizer
6.9 Bayer AG
6.10 Lupin Limited
6.11 Johnson & Johnson
6.12 Actelion Ltd
6.13 Ranbaxy Laboratories Limited
6.14 Other Notable Players

Companies Mentioned

  • Novartis AG
  • Astra zeneca
  • Daiichyi Sankyo Co. Ltd
  • Takeda Pharmaceutical
  • Sanofi
  • Merck & Co
  • Boehinger Ingelheim
  • Pfizer
  • Bayer AG
  • Lupin Limited
  • Johnson & Johnson
  • Actelion Ltd
  • Ranbaxy Laboratories Limited